Clinical Trials Insight: 700050418
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2010
At a glance
- Drugs KP 106; Lisdexamfetamine
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Pharmacokinetics
- 12 Jan 2010 Positive results reported in a KemPharm media release.
- 12 Jan 2010 Status changed from recruiting to completed as reported in a KemPharm media release.
- 28 Oct 2009 New trial record.